Michelle Fay Cortez
There Is a Magic Bullet for Some Cancers. What If It Misses?
J&J to Build Blood-Cancer Push With Controversial China Biotech
The Quest for a Weight-Loss Drug That Actually Works
Gel reduces testosterone in testes, replaces it elsewhere.
What was supposed to create an era of new cures didn’t work out that way, at least not at first.
Biohacking a Ripped Frog
Data on Fish-Oil Pill May Justify Amarin's Surging Stock Price
Medtronic, which sells about $2 billion worth of diabetes devices a year, has come to regard the DIY community as allies.
There’s clear evidence that male rats exposed to high levels of radiation used in mobile phones developed cancerous heart tumors.
Alzheimer's Drug New Data Shows More Study Likely Needed
Opioid Alternative From Pfizer and Lilly Shows Promise in Study
Biotech Investor Ousted Over Harassment Claims Sues
Novel Cell Therapy Offers Promise for Deadly Brain Infection
Vericel’s FDA-approved MACI procedure has a small but valuable audience.
Amarin's 475% Surge Leaves Its Holders Flush and Sellers Crushed
Roche Left Seeking a Niche as Merck Dominates Lung-Cancer Market
Medtronic Agrees to Buy Mazor Robotics in $1.6 Billion Deal
This Cartridge of Plastic Beads Can Filter Blood During Surgery
Liu Qiangdong flew home to China not long after his arrest, raising questions about why he was freed so quickly.
A Year After Cancer Milestone, Novartis’s Barrett Talks Next Steps